Kent Imaging Inc. is accelerating its growth through a US$15M investment by TVM Life Science Innovation II SCSp

CALGARY, January 13, 2021 /EIN Presswire/ – Kent Imaging, an innovator in the tissue imaging market, announced today its partnership with TVM Life Science Innovation II SCSp to accelerate the global commercialization of its industry leading SnapshotNIR® product.

SnapshotNIR utilizes near infrared light to determine tissue oxygen saturation (StO2), which is a key indicator of tissue health. Snapshot NIR assesses the microcirculation and conveys a comprehensive picture of tissue health and the healing capacity of wounds or surgical tissue. This FDA cleared, non-invasive approach to tissue assessment brings value to healthcare delivery in various clinical settings including wound care, plastic and reconstructive surgery, and vascular surgery.

“We are enormously proud to partner with TVM, a world-class venture capital fund to enhance Kent’s position as a major player in diagnostic tissue health assessment. The confidence expressed by TVM in Kent’s products and technology reinforces our leadership in bringing innovation to this critical market. With this investment, Kent will expand on its product line, its partnerships and accelerate the introduction of this novel technology globally.” – Pierre Lemire, CEO

“Kent Imaging commercializes innovative oxygenation imaging products targeting limb preservation and reconstructive surgical markets. This is an area with clear unmet need as non-healing wounds are a huge burden with respect to patient outcome and ever rising healthcare costs. TVM’s investment will further establish Kent Imaging on the global stage. We see Kent’s technology as the next major imaging modality and we are excited to be a part of the initiative to bring this technology to the global market. Kent Imaging will benefit from TVM Capital Life Science’s European and North American network to facilitate its market access abroad.” – Dr. Luc Marengere, Managing Partner, TVM Capital Life Science

In addition to the investment, Kent Imaging will also benefit with the addition of Dr. Marengere and Dr. Alexandra MacLean, a Principal with TVM Capital Life Science, to its Board of Directors.

About Kent Imaging Inc.

Kent Imaging, located in Calgary, Alberta, Canada, is a leading innovator in oxygenation imaging, who develops, manufactures and markets medical technology that supports real-time decision making in wound care, vascular and surgical sub-specialties. Kent holds multiple patents in oxygen imaging technology and continues to provide innovative and advanced diagnostic imaging solutions to aid healthcare systems nationally and internationally. For more information about Kent Imaging, visit

About TVM Capital Life Science

TVM Capital Life Science is providing venture capital to the international pharmaceutical, biopharmaceutical and medical technology industries with more than 35-years of transatlantic investment track record and more than US$2.0B raised. With its advisory, corporate finance and investment teams located in Montreal and Munich, the TVM Capital Life Science team provides investors, as well as entrepreneurs and innovation-seeking biopharmaceutical companies, access to global life science innovation and provides paths for successful tech transfer and commercialization for the benefit of patients and investors alike.

The TVM Capital Life Science team looks back on more than 140 investments and over 100 exits, including more than 45 initial public offerings on all major U.S. and European stock exchanges. The team has gained unrivalled international investment and business development experience with their track record of dedicated board work, significant contribution to global networks in the world of life science research and product development, and a direct knowledge of the local markets. More information:

EIN Presswire release:

Kent Imaging Inc. Receives FDA 510(k) Clearance on SnapshotNIR V3.0

CALGARY, January 6, 2021 /EIN Presswire/ – Kent Imaging announced today the FDA 510(k) clearance for SnapshotNIR V3.0 (KD204) – now available for shipping. This upgrade provides significant feature enhancements to the imaging technology that advances tissue assessment in acute and chronic wounds. The multitude of advancements include the ability to image most skin tones (overcoming the melanin barrier), linear and surface area wound measurements, easy report generation with image comparisons, and enhanced patient file management, to name a few.

SnapshotNIR utilizes near infrared light to determine tissue oxygen saturation (StO2), which is a key indicator of tissue health. Ideal for microcirculation assessment, it conveys a comprehensive picture of the healing capacity of wounds or surgical tissue. This critical information is used to support clinical judgement in choosing, evaluating, and tracking treatment and surgical options throughout the care continuum.

“We are excited to release this enhanced version of SnapshotNIR as part of Kent’s dedication to bringing innovation to this critical market. Robust features asked for by front-line wound care specialists and reconstructive surgeons have been incorporated, delivering a product that can easily track and document wound healing progress and support therapeutic decisions,” noted Pierre Lemire, CEO. “SnapshotNIR V3.0 continues to support the goal of delivering on solutions that aid wound care and surgical specialists in improving patient outcomes and reducing complications.”

About Kent Imaging Inc.

Kent Imaging, located in Calgary, Alberta, Canada, is a leading innovator in oxygenation imaging, who develops, manufactures, and markets medical technology that supports real-time decision making in wound care, vascular and surgical sub-specialties. Kent holds multiple patents in oxygen imaging technology and continues to provide innovative and advanced diagnostic imaging solutions to aid healthcare systems nationally and internationally. For more information about Kent Imaging, visit

Western Economic Diversification Canada awards Kent Imaging with an investment of $1.75M through the Business Scaleup Program.

Oxygen is the key to life. Kent Imaging provides solutions to instantly measure tissue oxygenation in acute and chronic wounds to help in assessing a wound’s capacity to heal. Kent designs, manufactures and distributes a medical imaging device, SnapshotNIR, from their corporate headquarters in Calgary, AB.

The investment provided through Western Economic Diversification Canada (WD) will be leveraged to expand Kent Imaging’s footprint on a global scale. We are very appreciative of WD, as not only are they providing financial support to industry through these programs, they are also facilitating collaboration between industry and all levels of government to accelerate the growth of the Healthtech Ecosystem in Alberta.

“We are very excited to be a recipient of investment through WD’s Business Scale-up program to assist Kent Imaging in leveraging our innovative imaging technology, SnapshotNIR. Kent’s goal is to provide physicians immediate insight into the ability of tissue to heal, thus improving outcomes and reducing complications during treatment. This investment allows us to accelerate our product innovation and expand our global technology footprint.”

Pierre Lemire, CEO, Kent Imaging

The official release by Western Economic Diversification Canada can be accessed here:

Evaluation and prognosis of patients with SnapshotNIR

Doctors Wendy Young, Michael An, and Samantha Dunn are Foot and Ankle Specialists associated with the Department of Veterans Affairs of Northport New York and Stonybrook University Hospital.

The team is investigating the potential uses of the SnapshotNIR near infrared spectroscopy camera within their podiatric clinics in the evaluation and progrnosis of their patients.

Dr. Wendy Young is the podiatric Residency Director of Department f Veterns Affairs of Northport New York and Stonybrook University Hospital. Doctor An and Doctor Dunn are both first year podiatry residents.

Kent Imaging and SerenaGroup® Research Foundation awarded prestigious AICE grant

September 22, 2020. Kent Imaging and SerenaGroup® Research Foundation, have received the prestigious Accelerating Innovations into Care (AICE)Market Access grant from Alberta Innovates, a research and innovation agency sponsored by the province of Alberta, Canada. AICE supports companies in commercializing innovative digital health technologies. The award will fund clinical trials investigating the novel diagnostic technology developed by Kent Imaging utilizing near infrared spectroscopy (SnapshotNIR). Kent has partnered with SerenaGroup® Research Foundation to conduct this pivotal research.

Near infrared spectroscopy measures oxygen levels in tissue in real time without the need for injected dyes or invasive probes.  SnapshotNIR captures the image without patient contact. The colors displayed on the screen correspond to the degree of tissue oxygenation:  blue represents low oxygen levels and red represents high.  At present, advanced wound and hyperbaric centers use transcutaneous oxygen (TCOM) to measure oxygenation; however, TCOM has numerous drawbacks: the results are operator dependent, it requires heated leads that are attached to the skin and the procedure takes an hour to complete.

The AICE grant will fund a multicenter head-to-head clinical trial comparing SnapshotNIR to TCOM. In addition, correlation between the SnapshotNIR readings and healing outcomes will allow the investigators to predict the best interventions for patients with diminished oxygenation. “Health innovators often face headwinds in generating the evidence necessary for implementing new solutions. The data generated in this trial will accelerate the path to impact for SnapshotNIR, and is fully aligned with our digital health strategy,” shared Tim Murphy, VP Health at Alberta Innovates.

“This new technology from Kent Imaging will allow clinicians to rapidly assess tissue oxygenation in patients with chronic wounds, which will avoid delays in diagnosis and treatment,” said Dr. Tomas Serena, Director of the SerenaGroup® Research Foundation. “I believe that SnapshotNIR will play a key role in limb preservation in our diabetic patients, allowing woundologists to identify the patients who will benefit from advanced modalities such as for hyperbaric oxygen therapy.”

“We are very excited to be working with Dr. Tomas Serena and the SerenaGroup® Research Foundation to establish definitively the value of SnapshotNIR in the prediction of wound healing. Kent Imaging’s goal is to provide innovative technology that helps physicians to heal wounds, improve outcomes and significantly reduce amputations. This study will take us a long way towards meeting this goal,” said Pierre Lemire, CEO at Kent Imaging. “We also want to acknowledge the ongoing support of the Alberta Government in bringing this paradigm changing technology to market.”

About Kent Imaging

Kent Imaging Inc., a Canadian company located in Calgary, Alberta, and leading innovator in oxygenation imaging, designs and manufactures imaging technology that employs near infrared spectroscopy to measure tissue oxygen saturation. The oxygenation information provides immediate insight into tissue viability supporting real-time decision making in wound care, vascular and surgical specialties to aid in the delivery of positive patient outcomes throughout the care continuum.  For more information about Kent Imaging, visit

About SerenaGroup® Research Foundation

The SerenaGroup® Research Foundation, a leader in wound healing research, conducts eight to nine clinical trials each year and publishes a dozen manuscripts annually. Dr. Serena has been the lead or Principal Investigator in over 100 clinical trials, including gene therapy, dressings, growth factors, topical and parenteral antibiotics, and CTP therapy.  His team has led the development of diagnostic imaging and biomarkers in the field of wound healing.  

About Alberta Innovates

Alberta Innovates invests in research, innovation and entrepreneurship to drive provincial economic growth and diversity. We ignite the power of innovation through our work with researchers, industry and entrepreneurs to move Alberta to a lower-carbon future, enhance the responsible use of land and water, and contribute to the improved health and well-being of Albertans.

Will Siewert Appointed Kent Imaging’s Vice President, Sales for the US Market

September 8, 2020. Kent Imaging announced today the appointment of Will Siewert as Vice President of Sales, USA.

Will Siewert is a multi-award winning strategic sales executive with nearly two decades of medical device experience, including commercial launches for perfusion assessment technologies of Spy, Luna, and Pinpoint. Prior to joining Kent Imaging in 2017 as the Sales Director, Mr. Siewert had roles as trainer and sales leader within multiple organizations including Lifecell, Karl Storz and Covidien. At Kent, Mr. Siewert is responsible for sales of the Snapshot product line, primarily in the reconstructive surgical and limb salvage markets, in the USA.

About Kent Imaging Inc.

Kent Imaging, located in Calgary, Alberta, Canada, is a leading developer of medical technology, who designs, manufactures and markets imaging technology for wound and surgical care. Kent holds multiple patents in medical technology and continues to provide innovative and advanced diagnostic imaging solutions to aid healthcare systems nationally and internationally. For more information about Kent Imaging, visit

New and novel methods of non-invasive vascular assessment: enhancing triage protocols in wound healing and limb salvage

This CE/CME/CECH webinar presented by Dr. Richard Neville, MD (Director, Inova Vascular) and moderated by Dr. Lee Rogers, DPM (Chief Medical Officer at Amputation Prevention Experts (APEx) Health Network), is supported through an unrestricted educational grant from Kent Imaging. A recording of the webinar will reside on the website for 12 months following the live event. Register now for what is sure to be an intriguing topic in the management of critical limb ischemia.

SnapshotNIR Shown to Correlate to TCOM in Recent Publication

Check out a new study measuring tissue oxygenation in hard-to-heal wounds published in the Journal of Wound Care , comparing the use of TCOM to NIRS imaging with SnapshotNIR. The lead author, Dr. Tom Serena, concluded that both forms of measurement were well correlated but that SnapshotNIR  provided a number of significant advantages: immediate point-of-care visualization of tissue oxygenation using a handheld device, the entire imaging procedure takes only a few minutes to perform and removes operator dependence, and with no patient contact, allows for measurements directly in the wound bed.  

SnapshotNIR Aids in Effective Clinical Decisions by Advancing Tissue Assessment

SnapshotNIR is the feature of an article titled “Assessing DFU Perfusion: Comparing the Tried & True to the Novel & New” published in the May 2020 issue of Today’s Wound Clinic. The authors, Windy Cole, DPM, and Stacey Coe, note the challenges and inaccuracy with standard non-invasive vascular assessment methods, such as TCOM, and seek to determine if near-infrared spectroscopy (NIRS) imaging can provide a more accurate picture of wound healing. Using a challenging diabetic foot ulcer case study, the authors conclude that SnapshotNIR is the future of managing wound care treatments for improved and timely healing. SnapshotNIR was able to track hemodynamic changes in wound tissues after revascularization, and that the changes noted in wound tissue oxygenation correlated to the clinical appearance of the wound. The imaging information captured added aided clinicians in determining appropriate and effective treatment choices for patients’ recovery. SnapshotNIR’s ability to produce instant and reproducible images, along with its portability makes it an excellent choice for clinicians and the healing of their patients’ wounds. 

Supporting Wound Care Services through Remote Diagnostic Imaging

I hope that you continue to stay safe in this challenging environment, while you strive to provide on-going care for your wound patients.  We appreciate that these are unprecedented times, and Kent Imaging is focused on supporting you and your patients through the “new normal” which is anything but.

We understand that proper wound care is essential to preserving tissue and limbs and that “time is tissue.” We’re seeing proactive clinics adopting telehealth and remote diagnostic technologies to assist with wound triage to ensure patients are effectively prioritized for inpatient care.

In order to assist with this transition, Kent Imaging has refocused its resources to meet the demand from existing SnapshotNIR customers to release an update that remotely provides an informative assessment of the wound and vascular status.  Our partners have been instrumental in the development of this solution and continue to determine the best way SnapshotNIR can help them keep their patients out of the hospitals.

By embracing new methods of care including remote diagnostics to support triage decisions, providers can better understand wound progression remotely, providing appropriate referrals to those who need them, and protecting the health of patients who are unable to come to the hospital or are at high risk for COVID-19.

Please don’t hesitate to contact Kent Imaging to learn more. We have set-up a support center to provide online access to technical and clinical expertise to assist your staff with remote deployment and image assessment.

Your sincerely,

This image has an empty alt attribute; its file name is Pierre-Lemire-Signature1945.png

Pierre Lemire

CEO, Kent Imaging